

S Senan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10861815/publications.pdf>

Version: 2024-02-01

44
papers

5,869
citations

279487

23
h-index

288905

40
g-index

45
all docs

45
docs citations

45
times ranked

6483
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. <i>Radiotherapy and Oncology</i> , 2022, 170, 165-168.	0.3	9
2	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. <i>ESMO Open</i> , 2022, 7, 100410.	2.0	10
3	Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. <i>ESMO Open</i> , 2021, 6, 100244.	2.0	40
4	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. <i>Annals of Oncology</i> , 2020, 31, 798-806.	0.6	131
5	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 191-201.	0.6	70
6	ADRIATIC: Eine Phase-III-Studie mit Durvalumab ± Tremelimumab nach gleichzeitiger Radiochemotherapie für Patienten mit SCLC im Stadium Limited Disease. , 2020, 74, .		0
7	Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling. <i>Radiotherapy and Oncology</i> , 2018, 127, 233-238.	0.3	10
8	Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 738-747.	0.4	36
9	Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. <i>Clinical Oncology</i> , 2018, 30, 17-22.	0.6	6
10	Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches. <i>Lung Cancer</i> , 2018, 123, 142-148.	0.9	18
11	Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry. <i>Lung Cancer</i> , 2017, 110, 14-18.	0.9	11
12	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv1-iv21.	0.6	1,456
13	Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?. <i>Annals of Oncology</i> , 2016, 27, 1973.	0.6	1
14	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v1-v27.	0.6	1,351
15	WE-AB-202-02: Incorporating Regional Ventilation Function in Predicting Radiation Fibrosis After Concurrent Chemoradiotherapy for Lung Cancer. <i>Medical Physics</i> , 2016, 43, 3794-3794.	1.6	0
16	Stereotactic body radiotherapy for central lung tumours. <i>British Journal of Radiology</i> , 2015, 88, 20150410.	1.0	3
17	Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy. <i>Annals of Oncology</i> , 2015, 26, 2196.	0.6	9
18	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	0.6	410

#	ARTICLE	IF	CITATIONS
19	Trimodality therapy for stage IIIA non-small cell lung cancer: Benchmarking multi-disciplinary team decision-making and function. <i>Lung Cancer</i> , 2014, 85, 218-223.	0.9	13
20	Radiographic Changes After Lung Stereotactic Ablative Radiotherapy (SABR) – Can We Distinguish Fibrosis From Recurrence? A Systematic Review of the Literature. <i>Practical Radiation Oncology</i> , 2013, 3, S11-S12.	1.1	11
21	Stage II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. <i>Annals of Oncology</i> , 2013, 24, 1543-1548.	0.6	261
22	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi89-vi98.	0.6	440
23	TH-A-WAB-11: A Novel Method to Determine Alpha/beta for Irradiated Normal Lung Tissue Using Computed Tomography Scans. <i>Medical Physics</i> , 2013, 40, 522-522.	1.6	0
24	Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands. <i>Annals of Oncology</i> , 2012, 23, 2743-2747.	0.6	147
25	Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. <i>Annals of Oncology</i> , 2011, 22, 132-138.	0.6	39
26	Stereotactic radiotherapy for stage I lung cancer: Current results and new developments. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2010, 14, 115-118.	0.6	25
27	Outcomes of stereotactic body radiotherapy (SBRT) in 175 patients with stage I NSCLC aged 75 years and older. <i>Journal of Clinical Oncology</i> , 2009, 27, 9545-9545.	0.8	0
28	Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 685-692.	0.4	510
29	Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer. <i>British Journal of Cancer</i> , 2007, 97, 276-276.	2.9	12
30	Lack of consensus on post-operative radiotherapy (PORT) fields used in non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2007, 25, 7658-7658.	0.8	0
31	Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. <i>British Journal of Cancer</i> , 2006, 94, 625-630.	2.9	88
32	The role of radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, ii223-ii228.	0.6	11
33	Defining target volumes for non-small cell lung carcinoma. <i>Seminars in Radiation Oncology</i> , 2004, 14, 308-314.	1.0	39
34	Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer – an analysis of data generated using slow™ CT scans. <i>Radiotherapy and Oncology</i> , 2001, 61, 93-99.	0.3	52
35	An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 32, 145-153.	0.9	25
36	Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 857-868.	0.4	114

#	ARTICLE	IF	CITATIONS
37	Multiple "slow" CT scans for incorporating lung tumor mobility in radiotherapy planning. International Journal of Radiation Oncology Biology Physics, 2001, 51, 932-937.	0.4	191
38	The use of CT-simulation and digitally reconstructed radiographs (DRR's) in setup verification allows for smaller planning target volumes in lung cancer. Lung Cancer, 2000, 29, 162.	0.9	3
39	An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. International Journal of Radiation Oncology Biology Physics, 1999, 43, 827-832.	0.4	56
40	BRACHYTHERAPY FOR RECURRENT HEAD AND NECK CANCER. Hematology/Oncology Clinics of North America, 1999, 13, 531-542.	0.9	14
41	Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. Radiotherapy and Oncology, 1999, 53, 247-255.	0.3	139
42	Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx.. Journal of Clinical Oncology, 1998, 16, 2213-2220.	0.8	62
43	Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clinical Cancer Research, 1997, 3, 31-8.	3.2	35
44	The diagnosis and treatment of nasal lymphoma, an important cause of upper respiratory tract destruction. Clinical Otolaryngology, 1992, 17, 563-566.	0.6	5